LONDON, September 30, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Immunomedics Inc. (NASDAQ: IMMU), Aeterna Zentaris Inc. (NASDAQ: AEZS), OPKO Health Inc. (NYSE: OPK), Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences Corporation (NASDAQ: EXAS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, September 29, 2014, the NASDAQ Composite ended at 4,505.85, down 0.14%, the Dow Jones Industrial Average finished the day 0.25% lower at 17,071.22, and the S&P 500 closed at 1,977.80, down 0.25%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 744.38, down 0.18%, while the index has advanced 0.92% in the last one month. Register for your complimentary reports on these five stocks at:

http://investor-edge.com/register

On Monday, Immunomedics Inc.'s stock recorded a trading volume of 1.77 million shares, higher than its three months average volume of 0.51 million shares. The stock finished the day at $3.84, up 9.09%, and registered an intraday range of $3.50 and $3.94. Immunomedics Inc.'s shares have surged 15.32% in the last one month and 7.26% in the past three months. However, the stock has declined 16.52% on YTD basis. Furthermore, the company's stock is trading above its 50-day moving average. The stock's 200-day moving average of $4.00 is above its 50-day moving average of $3.33. Additionally, shares of Immunomedics Inc. have a Relative Strength Index (RSI) of 58.51. Sign up and read the free notes on IMMU at:

www.Investor-Edge.com/IMMU-30Sep2014 [http://www.investor-edge.com/IMMU-30Sep2014 ]

Aeterna Zentaris Inc.'s stock fell by 0.75%, to close Monday's session at $1.32, after oscillating between $1.31 and $1.34. The stock recorded a trading volume of 0.51 million shares, below its three months average volume of 1.08 million shares. Over the last one month and from the beginning of 2014, Aeterna Zentaris Inc.'s shares have lost 12.00% and 4.35%, respectively. However, over the past three months, the stock has gained 18.92%. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $1.29 is above its 200-day moving average of $1.23. Further, Aeterna Zentaris Inc.'s stock has an RSI of 46.96. The complimentary notes on AEZS can be downloaded as in PDF format at:

www.Investor-Edge.com/AEZS-30Sep2014 [http://www.investor-edge.com/AEZS-30Sep2014 ]

On Monday, OPKO Health Inc.'s stock finished the session 0.47% higher at $8.64. A total of 3.02 million shares were traded, which was above its three months average volume of 2.32 million shares. The stock moved between $8.47 and $8.67 during the session. Over the last one month and past three months, OPKO Health Inc.'s shares have fallen by 2.92% and 5.05%, respectively. However, the stock has gone up 2.37% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $8.80 is greater than its 200-day moving average of $8.77. Shares of OPKO Health Inc. have an RSI of 49.93. Register for free on Investor-Edge and access the latest research on OPK at:

www.Investor-Edge.com/OPK-30Sep2014 [http://www.investor-edge.com/OPK-30Sep2014 ]

Shares in Navidea Biopharmaceuticals Inc. fluctuated between $1.26 and $1.35 before ending Monday's session up 4.72%, at $1.33. The stock reported a trading volume of 0.60 million shares, which was at par with its three months average volume. Further, shares of Navidea Biopharmaceuticals Inc. have plummeted 6.99% over the last one month and 10.14% over the past three months. Also, the stock has declined 35.75% on YTD basis. The company's stock is trading above its 50-day moving average. The stock's 200-day moving average of $1.64 is greater than its 50-day moving average of $1.30. Moreover, shares of Navidea Biopharmaceuticals Inc. have an RSI of 46.07. The complete research on NAVB is available for free at:

www.Investor-Edge.com/NAVB-30Sep2014 [http://www.investor-edge.com/NAVB-30Sep2014 ]

Exact Sciences Corp.'s stock gained 1.25%, to close Monday's session at $19.37, after vacillating between $18.76 and $19.62. The stock recorded a trading volume of 0.95 million shares, below its three months average volume of 1.79 million shares. Over the last one month, Exact Sciences Corp.'s shares have lost 7.10%. However, over the past three months and from the beginning of 2014, the stock has rallied 16.48% and 64.85%, respectively. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $18.69 is above its 200-day moving average of $14.97. Further, Exact Sciences Corp.'s stock has an RSI of 46.15. Free in depth research on EXAS is available at:

www.Investor-Edge.com/EXAS-30Sep2014 [http://www.investor-edge.com/EXAS-30Sep2014 ]

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge